RT Journal Article
SR Electronic
T1 Persistence of neutralizing antibodies a year after SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.13.21260426
DO 10.1101/2021.07.13.21260426
A1 Anu Haveri
A1 Nina Ekström
A1 Anna Solastie
A1 Camilla Virta
A1 Pamela Österlund
A1 Elina Isosaari
A1 Hanna Nohynek
A1 Arto A. Palmu
A1 Merit Melin
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.07.13.21260426.abstract
AB Understanding for how long antibodies persist following Severe acute respiratory coronavirus 2 (SARS-CoV-2) infection provides important insight into estimating the duration of immunity induced by infection.We assessed the persistence of serum antibodies following wild-type SARS-CoV-2 infection six and twelve months after diagnosis in 367 individuals of whom 13% had severe disease requiring hospitalization. We determined the SARS-CoV-2 spike (S-IgG) and nucleoprotein IgG concentrations and the proportion of subjects with neutralizing antibodies (NAb). We also measured the NAb titers among a smaller subset of participants (n=78) against a wild-type virus (B.1) and three variants of concern (VOCs): Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2).We found that NAb against the wild-type virus and S-IgG persisted in 89% and 97% of subjects for at least twelve months after infection, respectively. IgG and NAb levels were higher after severe infection. NAb titers were significantly lower against variants compared to the wild-type virus.Competing Interest StatementA.A.P. is an investigator in studies for which the Finnish Institute for Health and Welfare has received research funding: Sanofi Pasteur, GlaxoSmithKline and Pfizer. The other authors report no potential conflicts of interest.Funding StatementThis study was funded by the Finnish institute for Health and Welfare and the Academy of Finland (Decision number 336431).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the ethical committee the Hospital District of Helsinki and Uusimaa (HUS) and registered under the Development of seroprevalence in Finland during the new coronavirus (SARS-CoV-2) epidemic serological population study protocol HUS/1137/2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request. The SARS-CoV-2 sequence data used in this study have been deposited in the GISAID EpiCoV™ Database under isolate codes EPI_ISL_407079, EPI_ISL_2590786 and EPI_ISL_2557176.